drugset
drugset / Trial / NCT04430842

Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S

NCT04430842 ↗

Phase 1 Completed 15 enrolled Quadriga Biosciences, Inc. Novotech (Australia) Pty Limited · collab
NaSequentialOpen-labelTreatment

Summary

This is a multi-center, open-label, dose escalation study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and maximum tolerated dose (MTD) of QBS10072S in patients with advanced or metastatic cancers with high LAT1 expression. The MTD of QBS10072S will be confirmed in patients with relapsed or refractory grade 4 astrocytoma.

Timeline

Start
2020-07-20
Primary completion
2022-09-21
Completion
2022-12-22

Drugs

EvaluationDrugModalityDoseRoute
Subject QBS10072S Unknown 3 mg/m2 Intravenous

Indications

astrocytoma (excluding glioblastoma) breast cancer cervical cancer cholangiocarcinoma colorectal cancer esophageal cancer gastric cancer kidney cancer lung cancer malignant pancreatic neoplasm melanoma metastatic malignant neoplasm in the brain ovarian cancer pleural mesothelioma prostate cancer sarcoma thymic carcinoma tongue cancer urinary bladder cancer